Clay Cohen1, Amber King, Chee Paul Lin, Gregory K Friedman, Kathy Monroe, Matthew Kutny. 1. From the *Department of Pediatrics, School of Medicine, †Division of Pediatric Emergency Medicine, Department of Pediatrics, ‡Center for Clinical and Translational Science, §Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.
Abstract
OBJECTIVES: Patients with febrile neutropenia are at high risk of morbidity and mortality from infectious causes. Decreasing time to antibiotic (TTA) administration is associated with improved patient outcomes. We sought to reduce TTA for children presenting to the emergency department with fever and neutropenia. METHODS: In a prospective cohort study with historical comparison, TTA administration was evaluated in patients with neutropenia presenting to the Children's of Alabama Emergency Department. A protocol was established to reduce delays in antibiotic administration and increase the percentage of patients who receive treatment within 60 minutes of presentation. One hundred pre-protocol patient visits between August 2010 and December 2011 were evaluated and 153 post-protocol visits were evaluated between August 2012 and September 2013. We reviewed individual cases to determine barriers to rapid antibiotic administration. RESULTS: Antibiotics were administered in 96.9 ± 57.8 minutes in the pre-protocol patient group, and only 35% of patients received antibiotics within 60 minutes of presentation and 70% received antibiotics within 120 minutes. After implementation of the protocol, TTA for neutropenic patients was decreased to 64.3 ± 28.4 minutes (P < 0.0001) with 51.4% receiving antibiotics within 60 minutes and 93.2% within 120 minutes. CONCLUSIONS: Implementing a standard approach to patients at risk for neutropenia decreased TTA. There are numerous challenges in providing timely antibiotics to children with febrile neutropenia. Identified delays included venous access (time to effect of topical anesthetics, and difficulty obtaining access), physicians waiting on laboratory results, and antibiotic availability.
OBJECTIVES:Patients with febrile neutropenia are at high risk of morbidity and mortality from infectious causes. Decreasing time to antibiotic (TTA) administration is associated with improved patient outcomes. We sought to reduce TTA for children presenting to the emergency department with fever and neutropenia. METHODS: In a prospective cohort study with historical comparison, TTA administration was evaluated in patients with neutropenia presenting to the Children's of Alabama Emergency Department. A protocol was established to reduce delays in antibiotic administration and increase the percentage of patients who receive treatment within 60 minutes of presentation. One hundred pre-protocol patient visits between August 2010 and December 2011 were evaluated and 153 post-protocol visits were evaluated between August 2012 and September 2013. We reviewed individual cases to determine barriers to rapid antibiotic administration. RESULTS: Antibiotics were administered in 96.9 ± 57.8 minutes in the pre-protocol patient group, and only 35% of patients received antibiotics within 60 minutes of presentation and 70% received antibiotics within 120 minutes. After implementation of the protocol, TTA for neutropenicpatients was decreased to 64.3 ± 28.4 minutes (P < 0.0001) with 51.4% receiving antibiotics within 60 minutes and 93.2% within 120 minutes. CONCLUSIONS: Implementing a standard approach to patients at risk for neutropenia decreased TTA. There are numerous challenges in providing timely antibiotics to children with febrile neutropenia. Identified delays included venous access (time to effect of topical anesthetics, and difficulty obtaining access), physicians waiting on laboratory results, and antibiotic availability.
Authors: Roland A Ammann; Nicole Bodmer; Andreas Hirt; Felix K Niggli; David Nadal; Arne Simon; Hulya Ozsahin; Udo Kontny; Thomas Kühne; Maja Beck Popovic; Annette Ridolfi Lüthy; Christoph Aebi Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Diana Volpe; Stephanie Harrison; Fran Damian; Pratik Rachh; Prerna S Kahlon; Lisa Morrissey; Jennifer Mack; Ayobami Akenroye; Anne M Stack Journal: Pediatrics Date: 2012-06-18 Impact factor: 7.124
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: María E Santolaya; Ana M Alvarez; Carmen L Avilés; Ana Becker; Claudio Mosso; Miguel O'Ryan; Ernesto Payá; Carmen Salgado; Pamela Silva; Santiago Topelberg; Juan Tordecilla; Mónica Varas; Milena Villarroel; Tamara Viviani; Marcela Zubieta Journal: Pediatr Infect Dis J Date: 2007-09 Impact factor: 2.129
Authors: Miriam L Gonzalez; Paula Aristizabal; Adriana Loera-Reyna; Dara Torres; Mario Ornelas-Sánchez; Laura Nuño-Vázquez; Marco Aguilera; Alicia Sánchez; Mitzy Romano; Rebeca Rivera-Gómez; George Relyea; Paola Friedrich; Miguela A Caniza Journal: JCO Glob Oncol Date: 2021-05
Authors: Charles A Phillips; Lamia P Barakat; Brad H Pollock; L Charles Bailey; Rinad S Beidas Journal: Pediatr Blood Cancer Date: 2022-01-19 Impact factor: 3.167
Authors: Kathy Monroe; Clay T Cohen; Kimberly Whelan; Amber King; Lisa Maloney; Janet Deason; John Charles Nichols; Gregory K Friedman; Matthew Kutny; Leslie Hayes Journal: Pediatr Qual Saf Date: 2018-08-09
Authors: Christopher McKinney; Amy Caruso-Brown; Kathleen Montgomery; Anne Gillespie; Rebecca Coughlin; Dawn Law; Anna Brouwer; Lauren Tytler; Joanne Hilden; Rachelle Nuss Journal: Pediatr Qual Saf Date: 2020-01-10